Markets

Pacific Edge at risk of losing ‘significant’ revenue stream

Dan Brunskill
Mon, 01 Aug 2022

Pacific Edge at risk of losing ‘significant’ revenue stream

The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)

Dan Brunskill
Mon, 01 Aug 2022

Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered. Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

Unlock all stories
free for 10 days

Trustworthy, balanced journalism every day from our growing team of New Zealand business reporters and commentators, plus more in our weekend magazine section, The Life.

Instant News Alerts based on keywords you choose or journalists you follow
Our Daily Digest of all stories at 6am, midday or 6pm
Comprehensive business and markets coverage
News via email, web and Apple/Android apps

Try for 10 days without paying and if you’re not convinced cancel with just two clicks.

Find out more

Subscribe now

Name

E-Mail Address

Password

Minimum password length of 8 characters.
Require at least one upper and lowercase, numeric, and special character. {{ registerForm.errors.get('password') }}

Confirm Password

We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.

Cardholder's Name

Card

You will be charged in 10 days unless you cancel beforehand. We will remind you three times before charging you.
All subscriptions auto renew but are easy to cancel.

I Accept The Terms Of Service {{ registerForm.errors.get('terms') }}

Tax: {{ taxAmount(selectedPlan) | currency }}

Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}

Or Subscribe with Google

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

Markets FREE

A2 shares plunge over FDA formula deferral

Staff reporters | Wed, 10 Aug 2022

A2 shares dropped 11% to $5.01 in early morning trading opened but made up a bit of lost ground by the end of the day.

Tourism

Tourism needs to 'embrace' job-sharing to spur recovery – report

Brent Melville | Wed, 10 Aug 2022

An industry that lost more than a third of its workforce during the pandemic needs to start thinking differently about work sharing.

Primary Sector

A2 Milk gets shot down because of issues in application

Rebecca Howard | Wed, 10 Aug 2022

The FDA continues to work around the clock to address current supply challenges, including reviewing a number of requests from manufacturers for enforcement discretion, as quickly as possible, a spokesperson said.

Pacific Edge at risk of losing ‘significant’ revenue stream

Subscribe now

Or Subscribe with Google

Not convinced yet?

Your company has a subscription

Team